Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A-Reference-Cited by-同舟云学术

Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A

Published:2019-01-25 Issue:2 Volume:3 Page:261-267
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Stanford Sophia¹,Pink Ruth¹,Creagh Desmond²,Clark Amanda³,Lowe Gillian⁴,Curry Nicola⁵,Pasi John⁶,Perry David⁷,Fong Sylvia⁸,Hayes Gregory⁸,Chandrakumaran Kandiah⁹,Rangarajan Savita¹

Affiliation:

1. Department of Hemophilia, Haemostasis and Thrombosis; Hampshire Hospitals NHS Foundation Trust; Basingstoke Hampshire UK

2. Haematology Department; Royal Cornwall Hospital; Truro Cornwall UK

3. Bristol Hemophilia Comprehensive Care Centre; University Hospitals Bristol NHS Foundation Trust; Bristol UK

4. Comprehensive Care Hemophilia Centre; University Hospitals Birmingham NHS Foundation Trust; Birmingham UK

5. Oxford Haemophilia and Thrombosis Centre; Oxford University Hospitals NHS Foundation Trust and Oxford Comprehensive BRC, Blood Theme; Oxford UK

6. Royal London Haemophilia Centre; Barts Health NHS Trust; London UK

7. Cambridge Haemophilia and Thrombophilia Centre; Cambridge University Hospitals NHS Foundation Trust; Cambridge UK

8. BioMarin Pharmaceutical Inc; Novato California

9. Peritoneal Malignancy Institute and Surgery; Hampshire Hospitals NHS Foundation Trust; Basingstoke Hampshire UK

Funder

BioMarin Pharmaceutical

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/rth2.12177/fullpdf

Reference47 articles.

1. Identifying and overcoming barriers to prophylaxis in the management of hemophilia;Petrini;Hemophilia,2007

2. Treatment for life for severe hemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment;Farrugia;Hemophilia,2013

3. Gene therapy for hemophilia;Chuah;J Thromb Haemost,2013

4. Guidelines for the management of hemophilia;Srivastava;Hemophilia,2013

5. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B;Nathwani;N Engl J Med,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies;Molecular Therapy - Methods & Clinical Development;2024-09

2. Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy;Current Gene Therapy;2024-08

3. The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution;Medicinal Research Reviews;2024-03-28

4. Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges;Genes & Diseases;2024-01

5. Understanding AAV vector immunogenicity: from particle to patient;Theranostics;2024